Moderna Stock Falls On Potential FDA Delay For Covid Vaccine In Teens

Moderna Stock Falls On Potential FDA Delay For Covid Vaccine In Teens
·2 min read

Moderna stock dipped Friday on a report the FDA is delaying its review of the company's Covid vaccine in teens.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting